Ono Pharmaceutical Co., Ltd. (OPHLY) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Osaka, 일본. 현재 CEO는 Gyo Sagara.
OPHLY 을(를) 보유 IPO 날짜 2012-10-02, 3,853 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $7.32B.
Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company headquartered in Osaka with a history dating back to 1717. The company develops, manufactures, and markets a diverse portfolio of prescription medications across oncology, cardiovascular, immunology, and other therapeutic areas, with leading products including OPDIVO for cancer treatment, FORXIGA for diabetes, ORENCIA for rheumatoid arthritis, and CORALAN for heart failure. Operating globally through its subsidiaries, Ono maintains a robust pipeline of drugs in development targeting a wide range of cancers, neurological disorders, autoimmune conditions, and other serious diseases. The company combines its heritage in pharmaceutical innovation with modern research capabilities to serve patients and healthcare systems worldwide.
